Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Open accessAbstract
BACKGROUND: Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. METHODS: We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. RESULTS: white cells) (P<0.001). The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group vs. 35.3% in the control group), anemia (11.8% vs. 19.7%), lymphopenia (15.1% vs. 10.7%), and pneumonia (13.7% vs. 7.9%). CONCLUSIONS: Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
3 of 7 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured
- Premisecitation
The phase 3 SWOG S0777 trial showed that adding bortezomib to lenalidomide plus dexamethasone lengthened progression-free survival in newly diagnosed myeloma patients not immediately eligible for autologous stem-cell transplantation (median, 41 vs. 29 months; hazard ratio, 0.74).
“The phase 3 Southwest Oncology Group (SWOG) S0777 trial of lenalidomide plus dexamethasone with or without bortezomib in patients with newly diagnosed myeloma for whom immediate autologous stem-cell transplantation was not indicated showed that the triplet combination resulted in longer progression-free survival (median, 41 months vs. 29 months; hazard ratio, 0.74), including among patients who”
Quote in the paperNot a substantial claim1 of 2 sources checked - Premisecitation
For multiple myeloma patients newly diagnosed and not eligible for autologous stem-cell transplant, lenalidomide with dexamethasone is a standard regimen.
“Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation.”
- Also stated in: § CONCLUSIONS · boosted
“these findings established the regimen of lenalidomide and dexamethasone as standard of care.”
Quote in the paperSubstantial claim1 of 2 sources checked - Also stated in: § CONCLUSIONS · boosted
- Premisecitation
In the CASTOR and POLLUX trials, patients with relapsed or refractory multiple myeloma and a high-risk cytogenetic profile had substantial progression-free survival and minimal residual disease benefits from daratumumab plus standard-of-care regimens after longer follow-up.
“However, in the CASTOR and POLLUX trials, among patients with relapsed or refractory multiple myeloma who had a high-risk cytogenetic profile, substantial benefits with respect to progression-free survival and minimal residual disease with daratumumab plus standard-of-care regimens were observed after a longer follow-up period.”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [16] source
The Efficacy section (p. 9) says the longer-follow-up POLLUX progression-free survival benefit was maintained across cytogenetic-risk subgroups, and the Discussion (p. 11) reports higher MRD-negativity rates overall. It does not establish an MRD benefit specifically in high-risk patients. Its CASTOR comparison (Discussion, p. 11) concerns patients with one prior therapy, not the high-risk cytogenetic subgroup. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [25] source
- Findingown data
Prespecified subgroup analyses of progression-free survival showed superiority of the daratumumab regimen over the control regimen in all subgroups except patients with hepatic impairment at baseline.
“Prespecified subgroup analyses of progression-free survival confirmed the superiority of the daratumumab regimen over the control regimen across all subgroups, except in the subgroup of patients who had hepatic impairment at baseline (Fig. 2).”
Quote in the paperNot a substantial claim - Findingown data
The progression-free survival benefit was maintained among patients aged 75 years or older, with a hazard ratio of 0.63 (95% CI, 0.44 to 0.92).
“The progression-free survival benefit was maintained among patients 75 years of age or older (hazard ratio, 0.63; 95% CI, 0.44 to 0.92).”
Quote in the paperSubstantial claim
- Findingown data
Among patients with a response of partial response or better, 80.3% in the daratumumab group and 65.7% in the control group sustained the response for 30 months.
“Among the patients who had a response (partial response or better), 80.3% (95% CI, 75.1 to 84.5) in the daratumumab group and 65.7% (95% CI, 58.6 to 71.8) in the control group sustained the response for 30 months.”
Quote in the paperSubstantial claim - Findingown data
Daratumumab plus lenalidomide and dexamethasone was associated with a higher incidence of neutropenia and infections.
“Daratumumab plus lenalidomide and dexamethasone was associated with a higher incidence of neutropenia and infections.”
Quote in the paperNot a substantial claim - Findingown data
Negative minimal residual disease status was associated with longer progression-free survival than positive status, regardless of trial treatment.
“Negative status for minimal residual disease was associated with longer progression-free survival than positive status, regardless of the trial treatment (Fig. S3 in the Supplementary Appendix).”
Quote in the paperNot a substantial claim - Findingown data
The percentage of patients with an overall response was 92.9% in the daratumumab group and 81.3% in the control group (P<0.001).
“The percentage of patients with an overall response was 92.9% in the daratumumab group and 81.3% in the control group (P<0.001).”
Quote in the paperSubstantial claim - Findingown data
The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group.
“The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group; the incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.”
Quote in the paperNot a substantial claim - Findingown data
After a median follow-up of 28.0 months, 138 patients had died: 62 (16.8%) in the daratumumab group and 76 (20.6%) in the control group.
“At a median follow-up of 28.0 months, 138 patients had died — 62 (16.8%) in the daratumumab group and 76 (20.6%) in the control group (Fig. S4 in the Supplementary Appendix).”
Quote in the paperSubstantial claim - Findingown data
The progression-free survival benefit of daratumumab was smaller in patients with a high-risk cytogenetic profile than in those with a standard-risk cytogenetic profile.
“The results of this interim analysis showed that the benefit of daratumumab with respect to progression-free survival was not as high in the subgroup of patients who had a high-risk cytogenetic profile as it was in the subgroup of patients who had a standard-risk cytogenetic profile.”
Quote in the paperNot a substantial claim - Findingown data
Every patient who was negative for minimal residual disease had a complete response or better.
“All the patients who were negative for minimal residual disease had a complete response or better.”
Quote in the paperNot a substantial claim - Findingown data
In the intention-to-treat population, the percentage of patients with complete response or better was significantly higher in the daratumumab group than in the control group (47.6% vs. 24.9%).
“In the intention-to-treat population, the percentage of patients with a complete response or better was significantly higher in the daratumumab group than in the control group (47.6% vs. 24.9%), as was the percentage with very good partial response or better (79.3% vs. 53.1%) (P<0.001 for both comparisons) (Table 2).”
Quote in the paperSubstantial claim - Findingown data
The incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.
“The incidence of infections of any grade was 86.3% in the daratumumab group and 73.4% in the control group; the incidence of grade 3 or 4 infections was 32.1% in the daratumumab group and 23.3% in the control group.”
Quote in the paperNot a substantial claim - Findingown data
After a median follow-up of 28.0 months, disease progression or death had occurred in 97 of 368 patients (26.4%) in the daratumumab group and 143 of 369 patients (38.8%) in the control group.
“At a median follow-up of 28.0 months, disease progression or death had occurred in 240 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 369 patients [38.8%] in the control group).”
Quote in the paperSubstantial claim - Findingown data
The estimated 30-month percentage of patients alive without disease progression was 70.6% in the daratumumab group and 55.6% in the control group.
“The Kaplan–Meier estimate of the percentage of patients who were alive without disease progression at 30 months was 70.6% (95% confidence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 49.5 to 61.3) in the control group.”
Quote in the paperSubstantial claim - Findingown data
The daratumumab group had a higher incidence of neutropenia and infections, including pneumonia, than the control group.
“The daratumumab group had a higher incidence of neutropenia and infections (including pneumonia) than the control group.”
Quote in the paperNot a substantial claim - Findingown data
Grade 3 or 4 neutropenia occurred in 50.0% of the daratumumab group and 35.3% of the control group.
“The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group and 35.3% in the control group), anemia (11.8% and 19.7%), lymphopenia (15.1% and 10.7%), pneumonia (13.7% and 7.9%), and leukopenia (11.0% and 4.9%).”
Quote in the paperNot a substantial claim - Findingown data
The percentage of patients negative for minimal residual disease at a threshold of 1 tumor cell per 10^5 white cells was more than three times as high in the daratumumab group as in the control group (24.2% vs. 7.3%, P<0.001).
“The percentage of patients who were negative for minimal residual disease (at a threshold of 1 tumor cell per 105 white cells) was more than 3 times as high in the daratumumab group as in the control group (24.2% vs. 7.3%, P<0.001) (Table 2).”
Quote in the paperSubstantial claim - Findingown data
In the intention-to-treat population, the percentage of patients with very good partial response or better was significantly higher in the daratumumab group than in the control group (79.3% vs. 53.1%).
“In the intention-to-treat population, the percentage of patients with a complete response or better was significantly higher in the daratumumab group than in the control group (47.6% vs. 24.9%), as was the percentage with very good partial response or better (79.3% vs. 53.1%) (P<0.001 for both comparisons) (Table 2).”
Quote in the paperSubstantial claim - Findingown data
Median treatment duration was longer in the daratumumab group than in the control group (25.3 vs. 21.3 months).
“The median duration of treatment was longer in the daratumumab group than in the control group (25.3 months vs. 21.3 months).”
Quote in the paperNot a substantial claim - Findingown data
Median overall survival was not reached in either treatment group.
“The median overall survival was not reached in either group, and follow-up for long-term survival is ongoing.”
Quote in the paperNot a substantial claim - Findingown data
The hazard ratio for disease progression or death in the daratumumab group compared with the control group was 0.56 (95% CI, 0.43 to 0.73; P<0.001).
“The hazard ratio for disease progression or death in the daratumumab group as compared with the control group was 0.56 (95% CI, 0.43 to 0.73; P<0.001) (Fig. 1).”
Quote in the paperSubstantial claim - Findingown data
Grade 3 or 4 pneumonia occurred in 13.7% of the daratumumab group and 7.9% of the control group.
“The most common adverse events of grade 3 or 4 were neutropenia (50.0% in the daratumumab group and 35.3% in the control group), anemia (11.8% and 19.7%), lymphopenia (15.1% and 10.7%), pneumonia (13.7% and 7.9%), and leukopenia (11.0% and 4.9%).”
Quote in the paperNot a substantial claim - Study design and conductown data
The two treatment groups had well-balanced demographic and clinical characteristics at baseline.
“Demographic and clinical characteristics of the two groups were well balanced at baseline (Table 1).”
Quote in the paperNot a substantial claim - Interpretationown data
The lower lenalidomide dose did not reduce the efficacy of the daratumumab-based regimen, as shown by a consistent progression-free survival benefit in patients with baseline creatinine clearance of 60 ml per minute or less.
“Nevertheless, the efficacy of the daratumumab-based regimen was not affected by the lower dose of lenalidomide, as shown by the consistent progression-free survival benefit in the subgroup of patients who had a baseline creatinine clearance level of 60 ml or less per minute.”
Quote in the paperSubstantial claim
- May combine two claims. 7
- Classified as probably not a substantial claim. 3
May combine two claims.
Findingown dataThe trial population was notably older: 99% of patients were 65 years or older and 44% were 75 years or older.
“Our trial population was notably older; 99% of the patients were 65 years of age or older, and 44% were 75 years of age or older.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataMedian progression-free survival was not reached in the daratumumab group and was 31.9 months in the control group.
“The median progression-free survival was not reached in the daratumumab group and was 31.9 months (95% CI, 28.9 to not reached) in the control group.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataIn patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, adding daratumumab to lenalidomide and dexamethasone produced significantly longer progression-free survival, a higher response rate, greater depth of response, and longer duration of response than lenalidomide and dexamethasone alone.
“In this trial involving patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, the addition of daratumumab to lenalidomide and dexamethasone resulted in significantly longer progression-free survival, a higher response rate, an increased depth of response, and a longer duration of response than lenalidomide and dexamethasone alone.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataRandomization was stratified by International Staging System disease stage, geographic region, and age.
“Randomization was stratified according to International Staging System disease stage (I vs. II vs. III, with higher stages indicating more severe disease) (see Table S1 in the Supplementary Appendix for details on the staging criteria), geographic region (North America vs. other), and age (<75 vs. ≥75 years).”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone givenA sample of 730 patients was estimated to give 80% power to detect a 25% lower risk of disease progression or death with daratumumab plus lenalidomide and dexamethasone than with lenalidomide and dexamethasone alone, using a log-rank test at a two-sided alpha of 0.05.
“We estimated that a sample of 730 patients would provide the trial with 80% power to detect a risk of disease progression or death that was 25% lower with daratumumab plus lenalidomide and dexamethasone than with lenalidomide and dexamethasone alone, using a log-rank test at a two-sided alpha level of 0.05.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductown dataThe primary analysis used the intention-to-treat population, which included every randomized patient.
“The primary analysis was performed in the intention-to-treat population, which included all patients who underwent randomization.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe percentage of patients discontinuing treatment because of adverse events was low in this trial and consistent with the safety profile seen in the POLLUX and ALCYONE trials.
“The percentage of patients who discontinued treatment because of these adverse events was low in our trial and was consistent with the safety profile observed in the POLLUX and ALCYONE trials, the latter of which represents a similar population of patients with newly diagnosed myeloma who were ineligible for stem-cell transplantation.”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductown dataThe trial randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, with 368 assigned to daratumumab plus lenalidomide and dexamethasone and 369 to lenalidomide and dexamethasone alone.
“We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group).”
- Also stated in: § PATIENTS AND TREATMENT · plain
“A total of 737 patients were randomly assigned — 368 to the daratumumab group and 369 to the control group.”
Quote in the paperSubstantial claim- Also stated in: § PATIENTS AND TREATMENT · plain
May combine two claims.
InterpretationreasoningPatients in the daratumumab group received less lenalidomide than those in the control group, possibly because of more adverse events leading to dose discontinuation or modification.
“Although patients in the daratumumab group received treatment for a longer period of time, they received less lenalidomide than the control group, possibly owing to a higher incidence of adverse events that led to dose discontinuations or dose modifications in this group.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationIn the FIRST trial primary analysis, grade 3 or 4 infections occurred in 29% of patients receiving lenalidomide and dexamethasone, a rate consistent with this trial's rates of 32.1% in the daratumumab group and 23.3% in the control group.
“However, the incidence of grade 3 or 4 infections was 29% with lenalidomide and dexamethasone in the primary analysis of the FIRST trial,5 which was consistent with the incidence in our trial (32.1% in the daratumumab group and 23.3% in the control group).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [5] source
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DRd is approved for newly diagnosed myeloma based on an international randomized trial showing benefit over Rd.
“DRd is approved for patients with newly diagnosed myeloma based on the results of an international multicenter randomized trial which showed benefit over lenalidomide plus dexamethasone (Rd).97”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [97]
Methods (Trial Design and Oversight; Randomization and Treatment; page unavailable) describes a randomized trial at 176 sites in 14 countries comparing DRd with Rd. The Discussion (page unavailable) reports significantly longer progression-free survival with DRd, but only in newly diagnosed patients ineligible for stem-cell transplantation. Our copy does not establish that DRd was approved for newly diagnosed myeloma; its approval statement concerns daratumumab monotherapy for heavily pretreated patients. (LLM, conf=0.88)
Experimental — accuracy not yet measuredDaratumumab is a cornerstone of standard-of-care multiple myeloma regimens with demonstrated survival benefit across all lines.
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [10]
The introduction describes daratumumab as an anti-CD38 antibody and reports clinical benefit in trials involving newly diagnosed and relapsed or refractory myeloma. The Results show improved progression-free survival in this trial’s newly diagnosed, transplant-ineligible patients. The paper does not establish an overall-survival benefit across all lines of treatment; its final overall-survival analysis was still planned. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMeta-analyses suggest that indefinite maintenance therapy is superior in terms of survival outcomes.
“Meta-analyses suggest that indefinite maintenance therapy is superior in terms of survival outcomes36”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [36]
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · see citing works
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · see citing works
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974 · see citing works
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632 · see citing works
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · see citing works
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · cited 2× · see citing works
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works
Self-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037 · see citing works
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · see citing works
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 991 · see citing works
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B. M. P., Bald, J., Plesner, T., Syed, K. W., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 961 · see citing works
Self-citationDurie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · cited 2× · see citing works
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationLonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works
Self-citationRöllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 610 · see citing works
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · see citing works
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444 · see citing works
Self-citationPalumbo, A., Rajkumar, S., Miguel, J. S. S., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hájek, R., Einsele, H., Anderson, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 385 · see citing works
Self-citationOverdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297 · see citing works
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271 · see citing works
Self-citationSpencer, A. G., Lentzsch, S., Weisel, K. C., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 269 · see citing works
Self-citationDurie, B. G. M., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A. A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0311-8 · Cited by 254 · see citing works
Self-citationDimopoulos, M. A., Miguel, J. F. S., Belch, A. R., White, D. J., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kım, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194282 · Cited by 213 · see citing works
Self-citationAdams, H., Stevenaert, F., Krejcik, J., der Borght, K. V., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C. W., Vanhoof, G., et al. (2018) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 163 · see citing works
Self-citationBahlis, N. J., Sutherland, H. J., White, D. J., Sébag, M., Lentzsch, S., Kotb, R. R., Venner, C. P., Gasparetto, C., Col, A. D., Neri, P. E., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858852 · Cited by 139 · see citing works
Self-citationMcCudden, C. R., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., et al. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1031 · Cited by 125 · see citing works
Self-citationClosed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints
Tang, D., & Geller, N. L. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01188.x · Cited by 81 · see citing works
Durie, B. G., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117003 · Cited by 34 · see citing works
Self-citationBahlis, N., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kim, K., Takezako, N., Moreau, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112697 · Cited by 21 · cited 2× · see citing works
“‖ Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).”
BackgroundMethodSelf-citationBeyond NEOD001 for systemic light-chain amyloidosis
Varga, C., Lentzsch, S., & Comenzo, R. L. (2018) · Blood · doi:10.1182/blood-2018-07-865857 · Cited by 20 · see citing works
Mateos, M.-V., Sonneveld, P., Hungria, V. T. M., Nooka, A. K., Estell, J., Barreto, W. G., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112554 · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,054 · see citing works
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883 · see citing works
“DRd has been recently approved for patients with newly diagnosed myeloma, based on the results of an international multicenter randomized trial.(87) PFS at 30 months was higher with DRd compared with Rd, 70.”
BackgroundMethodvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 892 · see citing works
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900 · see citing works
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 802 · see citing works
“Daratumumab, lenalidomide, dexamethasone (DRd) has shown significant activity in patients who are not candidates for transplantation, and is an additional alternative to VRd.(88)”
BackgroundMethodInfluentialVoorhees, P. M., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R. W., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 698 · see citing works
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534 · see citing works
Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447 · see citing works
Self-citationD’Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M., Dall’Olio, D., van de Donk, N. W. C. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02614 · Cited by 433 · see citing works
“917 (0) 750 (23) 585 (36) 437 (42) 326 (47) 252 (52) 188 (76) 133 (102) 83 (137) 47 (162) 24 (181) 195 (0) 141 (5) 93 (6) 63 (8) 45 (10) 32 (11) 26 (14) 20 (19) 10 (27) 7 (27) 3 (31) Time (months)”
Self-citationCavo, M., Gay, F., Beksaç, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381 · see citing works
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370 · see citing works
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 362 · see citing works
Self-citationMalard, F., Neri, P. E., Bahlis, N. J., Terpos, E., Moukalled, N. M., Hungria, V., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 368 · see citing works
Self-citationClinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Oliva, S., D’Agostino, M., Boccadoro, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00001 · Cited by 291 · see citing works
“(50) NTE NDMM: - DaraRd arm (368) - Rd arm (369) NGS (10−5 ) Longitudinal Dara-Rd: 24.”
BackgroundIsatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400712 · Cited by 284 · see citing works
Self-citationMultiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277 · see citing works
Self-citationMoreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 280 · see citing works
“The approval of daratumumab-based regimens (dara-tumumab plus bortezomib plus melphalan plus prednisone [ALCYONE trial] 41,42 and daratumumab plus lenalidomide plus dexamethasone [MAIA trial] 43 ) as the front-line therapy for myeloma is making treat-ment decisions challenging.”
Self-citationCosta, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T. M., Godby, K. N., Silbermann, R. W., Dhakal, B., Bal, S., Giri, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01935 · Cited by 267 · see citing works
“(%) Bone disease 43 (81) 29 (63) 18 (75) 90 (73) Renal failure 2 (4) 8 (17) 6 (25) 16 (13) Anemia 22 (42) 30 (65) 20 (83) 72 (59) Hypercalcemia 8 (15) 7 (15) 7 (29) 22 (18) Immunoglobulin isotype, No.”
InfluentialKumar, S. K., Jacobus, S. J., Cohen, A. D., Weiss, M., Callander, N. S., Singh, A. K., Parker, T. L., Menter, A. R., Yang, X., Parsons, B. M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30452-6 · Cited by 260 · see citing works
Self-citationMateos, M., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30070-3 · Cited by 259 · see citing works
Self-citationDurie, B. G. M., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A. A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0311-8 · Cited by 254 · see citing works
Self-citationBahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kım, K., Takezako, N., Moreau, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0711-6 · Cited by 237 · see citing works
“Consistent tolerability was also observed with daratumumab in the phase 3 MAIA study of D-Rd versus Rd in patients with NDMM who are ineligible for transplantation (median follow-up, 28 months) [15].”
BackgroundSelf-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works
“More recently, several randomized trials showed a significant benefit for NDMM patients when adding daratumumab to the standard regimens with bortezomib, melphalan and prednisone [88], bortezomib, thalidomide and dexamethasone [89] or lenalidomide and dexamethasone [90].”
BackgroundATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Virgilio, F. D., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 231 · see citing works
“However, CD38-specific agents (including the FDA-approved monoclonal antibody daratumumab) are currently used with the aim of eradicating CD38-expressing myeloma cells (Facon et al , 2019), and ENPP1 blockers are still in preclinical development (Carozza et al , 2020).”
Palladini, G. O., Kastritis, E., Maurer, M. S., Zonder, J. A., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., et al. (2020) · Blood · doi:10.1182/blood.2019004460 · Cited by 212 · see citing works
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166 · see citing works
“gov, NCT02195479 demonstrated favorable results with the addition of daratumumab to standard induction therapies in subgroup analyses of untreated MM patients with high-risk disease, although interpretation of these results is limited due to the small number of patients [89,90].”
ResultCAR-T cell therapy in multiple myeloma: Current limitations and potential strategies
Zhang, X., Zhang, H., Lan, H., Wu, J., & Xiao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101495 · Cited by 173 · see citing works
“With the increasing understanding of MM pathogenesis and the application of novel therapeutic agents, such as proteasome inhibitors (bortezomib, ixazomib, and carfi lzomib), immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), and monoclonal antibodies (daratumumab, isatuximab, and elotuzumab), as wel…”
BackgroundDimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M. M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 196 · see citing works
“DaraRd 72 , DaraVM plus prednisone 73 and VRd 74 are the SOC regimens previously recommended by the EHA 11,12 for the treatment of transplant-ineligible patients with NDMM.”
Self-citationNCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
Kumar, S. K., Callander, N. S., Hillengaß, J., Liedtke, M., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0049 · Cited by 161 · see citing works
Self-citationGoldschmidt, H., Mai, E. K., Bertsch, U., Fenk, R. R., Nievergall, E., Tichy, D., Besemer, B., Dürig, J., Schroers, R., von Metzler, I., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00263-0 · Cited by 162 · see citing works
Self-citationMateos, M., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W. G., Corradini, P., Min, C., Medvedova, E., Weisel, K. C., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 160 · see citing works
Self-citationChromosome 1q21 abnormalities in multiple myeloma
Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154 · see citing works
Self-citationEmerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 157 · see citing works
San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood · doi:10.1182/blood.2020010439 · Cited by 153 · see citing works
Self-citationLeypoldt, L. B., Tichy, D., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Munder, M., Reinhardt, H. C., Nogai, A., Görner, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01696 · Cited by 150 · see citing works
“It is allowed to include patients in the trial after 1 cycle (4 weeks) of any antimyeloma fi rst-line treatment 4.”
BackgroundSelf-citationPérez, C., Botta, C., Zabaleta, A., Puig, N., Cedena, M., Goicoechea, I., Alameda, D., José‐Eneriz, E. S., Merino, J., Rodríguez‐Otero, P., et al. (2020) · Blood · doi:10.1182/blood.2019004537 · Cited by 146 · see citing works
Usmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 152 · see citing works
“…observed with frontline daratumumab plus lenalidomide and dexamethasone (D-Rd) triplet therapy versus lenalidomide and dexamethasone (Rd) alone in the phase 3 MAIA study 8,13,14 , which set a new benchmark for the transplant-ineligible population, with a median overall survival of 7.5 years 14 .”
InfluentialSelf-citationDimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00940 · Cited by 140 · see citing works
“0 (1-63) cycles; the median (range) duration of daratumumab monotherapy was 5.”
BackgroundSelf-citationMultiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 137 · see citing works
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Sonneveld, P., Chanan-Khan, A. A., Weisel, K. C., Nooka, A. K., Masszi, T., Beksaç, M., Špıčka, I., Hungria, V., Munder, M., Mateos, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02734 · Cited by 129 · see citing works
“0 (1-63), and median (range) duration of daratumumab monotherapy was 9.”
BackgroundSelf-citationFacon, T. T. F., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S. K., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01488-8 · Cited by 129 · see citing works
“The safety profile of D-Rd in frailty subgroups was generally consistent with the overall population of MAIA [14]; although higher rates of grade 3/4 neutropenia and pneumonia were observed with D-Rd in the frail subgroup than in the total–non-frail subgroup, these events were clinically manageable.”
BackgroundMethodResultInfluentialSelf-citationUsmani, S. Z., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B. C., Hita, S., Valent, J. N., Rosenzweig, M. A., Zonder, J. A., Dhodapkar, M. V., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30354-9 · Cited by 129 · see citing works
Self-citationCosta, L. J., Derman, B. A., Bal, S., Sidana, S., Chhabra, S., Silbermann, R. W., Ye, J. C., Cook, G., Cornell, R. F., Holstein, S. A., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01012-4 · Cited by 124 · see citing works
“testing all patients to testing only those with CR [15, 17, 19, 22, 28, 54, 73].”
BackgroundSelf-citationMultiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Dimopoulos, M. A., Moreau, P., Terpos, E., et al. (2021) · PubMed · doi:10.1097/hs9.0000000000000528 · Cited by 124 · see citing works
“001).(45) Other approved regimens in this setting include bendamustine plus prednisone(46) and melphalan, prednisone and lenalidomide (MPR),(47) but they are not routinely used and cannot be considered as standards of care.”
BackgroundSelf-citationMultiple myeloma with high-risk cytogenetics and its treatment approach
Hanamura, I. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03353-5 · Cited by 122 · see citing works
“The phase 3 MAIA study showed that the addition of Dara to Rd significantly improved PFS and MRD-negativity rates [110] (Table 2).”
BackgroundPathway network of pyroptosis and its potential inhibitors in acute kidney injury
Li, N., Wang, Y., Wang, X., Sun, N., & Gong, Y.-H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106033 · Cited by 123 · see citing works
Leleu, X. P., Hulin, C., Lambert, J., Bobin, A., Perrot, A., Karlin, L., Roussel, M., Montes, L., Chérel, B., Chalopin, T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03050-2 · Cited by 121 · see citing works
“…approved in combination with lenalidomide and dexamethasone (the triplet-based DRd regimen) in patients with newly diagnosed multiple myeloma (NDMM) that are transplant-ineligible (TI) and is considered the best SOC to date on the basis of a median progression-free survival (PFS) of 62 months 1–3 .”
Self-citationDaratumumab or active monitoring for high-risk smoldering multiple myeloma
Dimopoulos, M. A., Voorhees, P. M., Schjesvold, F., Cohen, Y. C., Hungria, V., Sandhu, I., Lindsay, J., Baker, R. I., Suzuki, K., Kosugi, H., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409029 · Cited by 121 · see citing works
Self-citationLandgren, O., Hultcrantz, M. L., Diamond, B. T., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C. R. C., Shah, U. A., Lu, S. X., Salcedo, M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0611 · Cited by 119 · see citing works
Dimopoulos, M. A., Jakubowiak, A. J., McCarthy, P. L., Orlowski, R. Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K. C., Ramasamy, K., Zweegman, S., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0273-x · Cited by 116 · see citing works
Self-citationImmune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 110 · see citing works
Usmani, S. Z., Nahi, H., Plesner, T., Weiss, B. M., Bahlis, N. J., Belch, A., Voorhees, P. M., Laubach, J. P., van de Donk, N. W. C. J., Ahmadi, T., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30081-8 · Cited by 109 · see citing works
Self-citationGiri, S., Grimshaw, A. A., Bal, S., Godby, K. N., Kharel, P., Djulbegović, B., Dimopoulos, M. A., Facon, T. T. F., Usmani, S. Z., Mateos, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4338 · Cited by 107 · see citing works
Self-citationCavo, M., Miguel, J. F. S., Usmani, S. Z., Weisel, K. C., Dimopoulos, M. A., Avet‐Loiseau, H., Paiva, B., Bahlis, N. J., Plesner, T., Hungria, V., et al. (2021) · Blood · doi:10.1182/blood.2021011101 · Cited by 106 · see citing works
Self-citationFacon, T., Venner, C. P., Bahlis, N. J., Offner, F., White, D. J., Karlin, L., Benboubker, L., Rigaudeau, S., Rodon, P., Voog, E., et al. (2021) · Blood · doi:10.1182/blood.2020008787 · Cited by 104 · see citing works
Self-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 94 · see citing works
Self-citationBahlis, N. J., Baz, R., Harrison, S. J., Quach, H., Ho, S.-J., Vangsted, A. J., Plesner, T., Moreau, P., Gibbs, S. D., Coppola, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00443 · Cited by 91 · see citing works
Self-citationOgiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood · doi:10.1182/blood.2019004332 · Cited by 92 · see citing works
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
Viola, D., Donà, A., Caserta, E., Troadec, E., Besi, F., McDonald, T., Ghoda, L. Y., Gunes, E. G., Sanchez, J. F., Khalife, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0810-4 · Cited by 90 · see citing works
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 89 · see citing works
Emerging agents and regimens for multiple myeloma
Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00980-5 · Cited by 88 · see citing works
Zand, L., Rajkumar, S. V., Leung, N., Sethi, S. M., Ters, M. E., & Fervenza, F. C. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101541 · Cited by 86 · see citing works
Daratumumab for treatment‐refractory antibody‐mediated diseases in neurology
Scheibe, F., Ostendorf, L., Prüß, H., Radbruch, H., Aschman, T., Hoffmann, S., Blau, I., Meisel, C., Alexander, T., & Meisel, A. (2022) · European Journal of Neurology · doi:10.1111/ene.15266 · Cited by 88 · see citing works
“Comorbidity of Patient #6 with smoldering multiple myeloma required treatment according to the MAIA protocol [12] for the first eight cycles followed by 12 further daratumumab cycles at monthly intervals.”
MethodCAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Rodríguez‐Lobato, L. G., Ganzetti, M., de Larrea, C. F., Hudecek, M., Einsele, H., & Danhof, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01243 · Cited by 85 · see citing works
“SLAMF7 is highly expressed on malignant plasma cells both, in NDMM and RRMM, regardless of the cytogenetic risk stratification (85).”
BackgroundInfluentialLarocca, A., Bonello, F., Gaïdano, G., D’Agostino, M., Offidani, M., Cascavilla, N., Capra, A., Benevolo, G., Tosi, P., Galli, M., et al. (2021) · Blood · doi:10.1182/blood.2020009507 · Cited by 85 · see citing works
“There is no evidence that lenalidomide improves the outcome of patients with high-risk cytogenetics; 2,23 triplets or more intensive regimens including newer drugs 5,6,24 are needed to overcome their bad prognosis.”
Dimopoulos, M. A., Špıčka, I., Quach, H., Oriol, A., Hájek, R., Garg, M. K., Beksaç, M., Bringhen, S., Katodritou, E., Chng, W. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02060 · Cited by 80 · see citing works
“These patients may receive continuous treatment with one or more agents received as induction, such as lenalidomide(9,14,15) and/or daratumumab.(8,16) In routine clinical practice, treatment duration may be limited because of toxicity and route of administration.”
BackgroundSelf-citationNovel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Puertas, B., González-Calle, V., Sobejano-Fuertes, E., Escalante, F., Queizán, J., Bárez, A., Labrador, J., Alonso-Alonso, J., de Coca, A. G., Cantalapiedra, A., et al. (2023) · Cancers · doi:10.3390/cancers15051558 · Cited by 82 · see citing works
“Currently, the standard of care (SoC) for MM consists of a combination of PIs and/or IMiDs and/or anti-CD38 antibodies [11,12], followed by ASCT and maintenance when the patient is eligible [13–17].”
BackgroundResultDuan, M., Nguyen, D. C., Joyner, C. J., Saney, C. L., Tipton, C. M., Andrews, J., Lonial, S., Kim, C. M., Hentenaar, I., Kosters, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112682 · Cited by 82 · see citing works
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, J. K., Kubicki, T., Raje, N. S., Vij, R., Reece, D. E., Berdeja, J. G., Derman, B. A., Rosenbaum, C. A., Richardson, P. G. G., Gurbuxani, S. K., et al. (2020) · Blood · doi:10.1182/blood.2020007522 · Cited by 74 · see citing works
Self-citationCho, S., Lin, L., Xing, L., Li, Y., Wen, K., Yu, T., Hsieh, P. A., Munshi, N. C., Wahl, J., Matthes, K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002524 · Cited by 74 · see citing works
“Lenalidomide (len) and pomalidomide (pom), 2 immunomodulatory drugs (IMiDs), are routinely used as a therapeutic backbone or partners in various MM treatment combinations throughout all disease settings.(31-35) IMiDs have direct antiproliferative and proapoptotic effects on MM, in addition to indirect anti-MM activity…”
BackgroundCurrent approaches to management of newly diagnosed multiple myeloma
Goel, U., Usmani, S. Z., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26512 · Cited by 73 · see citing works
“No significant difference in PFS was found between KCd + ASCT + KCd and KRd alone (53 months vs. 55.3 months, HR = 0.88, p = .45).24 Nevertheless, KCd may be a more economical alternative for NDMM as compared to VRd.77 4.1.2 | Quadruplet regimens Daratumumab is a monoclonal antibody targeting CD38.”
BackgroundInfluentialSelf-citationPoczta, A., Rogalska, A., & Marczak, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091841 · Cited by 73 · see citing works
“The addition of daratumumab improved the efficacy of both VMP and RD [82].”
BackgroundHow I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 72 · see citing works
Self-citationVirus-specific T-cell therapies for patients with primary immune deficiency
Keller, M. D., & Bollard, C. M. (2020) · Blood · doi:10.1182/blood.2019000924 · Cited by 67 · see citing works
Multiple myeloma with acute light chain cast nephropathy
Leung, N., & Rajkumar, S. V. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00806-w · Cited by 67 · see citing works
Stege, C. A. M., Nasserinejad, K., van der Spek, E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03143 · Cited by 66 · see citing works
“t(14;16) 2 out of 55 (4) High-risk cytogenetic disease 11 out of 56 (20)”
BackgroundInfluentialRosiñol, L., Oriol, A., Ríos, R., Blanchard, M. J., Jarque, I., Bargay, J., Hernández, M. T., Cabañas, V., Carrillo‐Cruz, E., Sureda, A. M., et al. (2023) · Blood · doi:10.1182/blood.2022019531 · Cited by 66 · see citing works
Offidani, M., Corvatta, L., Morè, S., Nappi, D., Martinelli, G., Olivieri, A., & Cerchione, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.624661 · Cited by 64 · see citing works
“As regard patients ineligible for ASCT, a great efficacy of daratumumab-containing combinations was reported by the phase III trials ALCYONE and MAIA, exploring daratumumab–bortezomib–melphalan–prednisone (DVMP) vs VMP and daratumumab–lenalidomide–dexamethasone (DRd) vs Rd, respectively.”
BackgroundInfluentialHou, J., Ye, J. C., Pu, J. J., Liu, H., Ding, W., Zheng, H., & Liu, D. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01077-3 · Cited by 63 · see citing works
Kumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00695-5 · Cited by 62 · see citing works
“TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY DISEASE With current therapies, patients with MM will experience their first relapse at variable intervals after diagnosis [7, 11, 12].”
BackgroundMethodSelf-citationFacon, T. T. F., Moreau, P., Weisel, K. C., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N. J., Basu, S., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02505-2 · Cited by 63 · see citing works
Self-citationMohan, M., Weinhold, N., Schinke, C., Thanedrarajan, S., Rasche, L., Sawyer, J. R., Tian, E., van Rhee, F., & Zangari, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16292 · Cited by 61 · see citing works
“More recently daratumumab combinations have shown clinical benefit in transplant-ineligible newly diagnosed multiple myeloma (NDMM) and is currently FDA-approved in the up-front setting in combination with melphalan/bortezomib and lenalidomide/dexamethasone (Mateos et al., 2018; Facon et al., 2019).”
BackgroundTreatment and disease‐related complications in multiple myeloma: Implications for survivorship
Chakraborty, R., & Majhail, N. S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25764 · Cited by 62 · see citing works
Engelhardt, M. M., Ihorst, G., Duque‐Afonso, J., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.242958 · Cited by 58 · see citing works
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., Grosicki, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.005 · Cited by 57 · see citing works
Self-citationMelflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Mateos, M., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y. A., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103120 · Cited by 58 · see citing works
Multiple Myeloma in the Time of COVID-19
Saleh, A. S. A., Sher, T., & Gertz, M. A. (2020) · Acta Haematologica · doi:10.1159/000507690 · Cited by 56 · see citing works
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 58 · see citing works
Sive, J. I., Cuthill, K., Hunter, H. M., Kazmi, M. A., Pratt, G., Smith, D., & British Society of Haematology (2021) · British Journal of Haematology · doi:10.1111/bjh.17410 · Cited by 57 · see citing works
“Daratumumab has been added to various induction regi- mens, demonstrating improved RR and PFS for NTE patients in combination with RD,84 and both PFS and OS with VMP,85,86 and PFS for TE patients in combination with VTD.84,87 OS data remain immature, but PFS data provide early evidence of benefit, and it is likely to…”
MethodHow to Treat High-Risk Myeloma at Diagnosis and Relapse
Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 55 · see citing works
Self-citationDeveloping next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 57 · see citing works
“Similarly, the demonstration that LENdex improved progression-free survival (PFS) compared to previously established standard therapies such as melphalan, thalidomide, and prednisone (MPT) in NDMM transplant ineligible patients paved the way to investigate combination studies with bortezomib and DARA (SWOG S0777, MAIA…”
BackgroundMonoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action
Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56 · see citing works
“9%) was observed in the daratumumab group (13).”
BackgroundOrgueira, A. M., González, M. S., Arias, J. Á. D., Rodríguez, B. A., Vence, N. A., López, Á. B., Blanco, A. A., Pérez, L. B., Raíndo, A. P., López, M. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01286-2 · Cited by 54 · see citing works
“These predictions need to be evaluated in other cohorts and in the context of the current realistic combinations that incorporate monoclonal antibodies and other immunotherapic approaches [44, 45].”
BackgroundAdditivity predicts the efficacy of most approved combination therapies for advanced cancer
Hwangbo, H., Patterson, S. C., Dai, A., Plana, D., & Palmer, A. C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00667-z · Cited by 51 · see citing works
Perspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 58 · see citing works
Current Treatment Strategies for Multiple Myeloma
Branagan, A. R., Lei, M. M., Lou, U. Y., & Raje, N. S. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00244 · Cited by 55 · see citing works
Self-citationEvaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 56 · see citing works
Balmaceda, N. B., Aziz, M., Chandrasekar, V. T., McClune, B. L., Kambhampati, S., Shune, L. O., Abdallah, A.-O. A., Anwer, F., Majeed, A., Qazilbash, M. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08451-x · Cited by 55 · see citing works
“Facon (2019) [20] MAIA 3 ND Daratumumab/lenalidomide/dexamethasone 364 73 25.”
BackgroundMaura, F., Boyle, E. M., Coffey, D. G., Maclachlan, K. H., Gagler, D. C., Diamond, B. T., Ghamlouch, H., Blaney, P., Ziccheddu, B., Cirrincione, A. M., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00657-1 · Cited by 55 · see citing works
“0 peaks) and point mutations/indels in 80 MM driver genes 16,26,27 (Supplementary Tables 7–9).”
InfluentialSelf-citation
- Authors
- Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Attal, M., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Ahmadi, T., Chiu, C., Wang, J., Van Rampelbergh, R., Uhlar, C. M., Kobos, R., Qi, M., & Usmani, S. Z.
- Affiliations
- Université de Lille (FR)
- Mayo Clinic (US)
- University of Southern Denmark (DK)
- The University of Texas MD Anderson Cancer Center (US)
- University of Calgary (CA)
- Karolinska University Hospital (SE)
- The University of Melbourne (AU)
- From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d’Hématologie, CHU de Toulouse–Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La...
- University of Alberta (CA)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- ORCID
- Facon, Thierry
- Kumar, Shaji
- Plesner, Torben
- Orlowski, Robert Z.
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
- Nahi, Hareth
- Hulin, Cyrille
- Quach, Hang
- Goldschmidt, Hartmut
- Perrot, Aurore
- Venner, Christopher P.
- Weisel, Katja
- Raje, Noopur
- Attal, Michel
- Macro, Margaret
- Frenzel, Laurent
- Leleu, Xavier
- Ahmadi, Tahamtan
- Chiu, Christopher
- Wang, Jianping
- Qi, Ming
- Usmani, Saad Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-30
- Volume
- 380
- Issue
- 22
- Pages
- 2104-2115
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10045721
- OpenAlex
- W2947874495
- Cited by
- 1,027
- References
- 32
- Citations by year
- 2026: 80 · 2025: 109 · 2024: 107 · 2023: 128 · 2022: 145 · 2021: 207 · 2020: 195 · 2019: 39 · 2018: 1 · 2012: 1
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Wolverhampton Intellectual Repository and E-Theses (University of Wolverhampton) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- Janssen Research and Development (-)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- daratumumab, lenalidomide, dexamethasone, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, neutropenia
- MeSH terms
- Lenalidomide, Progression-Free Survival, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read under definition version 3 (extract-v3) on 2026-09-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-09-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
